{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:48:58Z","timestamp":1788515338377,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing interstitial lung disease with a poor prognosis.\n                      <jats:sup>68<\/jats:sup>\n                      Ga-labeled FAP ligands exhibited highly promising results due to the crucial role of activated fibroblasts in fibrosis imaging of the lung. However,\n                      <jats:sup>18<\/jats:sup>\n                      F-labeled FAP ligands might provide qualitatively much higher imaging results with accompanying economic benefits due to large-scale production. Thus, we sought to investigate the potential of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FAPI-74 prospectively in a small patient cohort.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Eight patients underwent both [\n                      <jats:sup>18<\/jats:sup>\n                      F]FAPI-74-PET\/CT and HRCT scans and were then compared with a control group without any fibrosing pulmonary disease. The tracer uptake of fibrotic lung areas was analyzed in synopsis with radiological and clinical parameters.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We observed a positive correlation between the fibrotic active volume, the Hounsfield scale, as well as the vital and diffusing capacity of the lung.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The initial results confirm our assumption that [\n                      <jats:sup>18<\/jats:sup>\n                      F]FAPI-74 offers a viable non-invasive assessment method for pulmonary fibrotic changes in patients with IPF.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-023-06564-y","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T02:02:21Z","timestamp":1703037741000},"page":"1605-1611","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Initial results with [18F]FAPI-74 PET\/CT in idiopathic pulmonary fibrosis"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5666-0559","authenticated-orcid":false,"given":"Yuriko","family":"Mori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasko","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Novruzov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduards","family":"Mamlins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"R\u00f6hrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horacio","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Soza-Ried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Monje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Sabbagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mat\u00edas","family":"Florenzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik L.","family":"Giesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Undurraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"key":"6564_CR1","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, et al. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788\u2013824.","journal-title":"Am J Respir Crit Care Med"},{"key":"6564_CR2","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","volume":"183","author":"B Ley","year":"2011","unstructured":"Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431\u201340.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"6564_CR3","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3390\/ijms20030593","volume":"20","author":"B Ballester","year":"2019","unstructured":"Ballester B, Milara J, Cortijo J. Idiopathic pulmonary fibrosis and lung cancer: mechanisms and molecular targets. Int J Mol Sci. 2019;20(3):593.","journal-title":"Int J Mol Sci"},{"key":"6564_CR4","first-page":"176","volume":"23","author":"R Sharif","year":"2017","unstructured":"Sharif R. Overview of idiopathic pulmonary fibrosis (IPF) and evidence-based guidelines. Am J Manag Care. 2017;23:176\u201382.","journal-title":"Am J Manag Care"},{"key":"6564_CR5","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1136\/annrheumdis-2020-217408","volume":"79","author":"C Schmidkonz","year":"2020","unstructured":"Schmidkonz C, Rauber S, Atzinger A, et al. Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging. Ann Rheum Dis. 2020;79:1485\u201391.","journal-title":"Ann Rheum Dis"},{"key":"6564_CR6","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1093\/rheumatology\/kez483","volume":"59","author":"DM Peelen","year":"2020","unstructured":"Peelen DM, Zwezerijnen BGJC, Nossent EJ, et al. The quantitative assessment of interstitial lung disease with positron emission tomography scanning in systemic sclerosis patients. Rheumatology. 2020;59:1407\u201315.","journal-title":"Rheumatology"},{"key":"6564_CR7","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1016\/S2665-9913(20)30421-5","volume":"3","author":"C Bergmann","year":"2021","unstructured":"Bergmann C, Distler JHW, Treutlein C, et al. 68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study. Lancet Rheumatol. 2021;3:e185\u201394.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"6564_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2967\/jnumed.121.261925","volume":"63","author":"R R\u00f6hrich","year":"2022","unstructured":"R\u00f6hrich R, Leitz D, Glatting FM, et al. Fibroblast activation protein\u2013specific PET\/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study. J Nucl Med. 2022;63(1):127\u201333.","journal-title":"J Nucl Med"},{"issue":"11","key":"6564_CR9","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1007\/s00259-022-05814-9","volume":"49","author":"ZT Rosenkrans","year":"2022","unstructured":"Rosenkrans ZT, Massey CF, Bernau K, et al. [68Ga]Ga-FAPI-46 PET for noninvasive detection of pulmonary fibrosis disease activity. Eur J Nucl Med Mol Imaging. 2022;49(11):3705\u201316.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"6564_CR10","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.220749","volume":"306","author":"Y Mori","year":"2023","unstructured":"Mori Y, Dendl K, Cardinale J, Kratochwil C, Giesel FL, Haberkorn U. FAPI PET: Fibroblast activation protein inhibitor use in oncologic and nononcologic disease. Radiology. 2023;306(2): e220749.","journal-title":"Radiology"},{"issue":"2","key":"6564_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2967\/jnumed.120.245084","volume":"62","author":"FL Giesel","year":"2021","unstructured":"Giesel FL, Adeberg S, Syed M, et al. FAPI-74 PET\/CT Using either\u00a018F-AlF or cold-jit\u00a068Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients. J Nucl Med. 2021;62(2):201\u20137.","journal-title":"J Nucl Med."},{"issue":"11","key":"6564_CR12","doi-asserted-by":"publisher","first-page":"7877","DOI":"10.1007\/s00330-023-09715-9","volume":"33","author":"Y Mori","year":"2023","unstructured":"Mori Y, Haberkorn U, Giesel FL. 68Ga- or 18F-FAPI PET\/CT-what it can and cannot. Eur Radiol. 2023;33(11):7877\u20138.","journal-title":"Eur Radiol."},{"key":"6564_CR13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, R\u00f6hrich M, Winter H, et al. 68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60:801\u20135.","journal-title":"J Nucl Med"},{"key":"6564_CR14","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.118.215913","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, Debus J, J\u00e4ger D, Flechsig P, Altmann A, et al. 68Ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP targeting agents in patients with various cancers. J Nucl Med. 2019;60:386\u201392.","journal-title":"J Nucl Med"},{"key":"6564_CR15","doi-asserted-by":"crossref","unstructured":"Giesel FL, Kratochwil C, Schlittenhardt J, Dendl K, Eiber M, Staudinger F, Kessler L, Fendler WP, Lindner T, Koerber SA, et al. Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET\/CT in cancer patients. Eur. J. Nucl. Med. Mol. Imaging 2021; 1\u20139.","DOI":"10.1007\/s00259-021-05307-1"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06564-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06564-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06564-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T02:03:28Z","timestamp":1713924208000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06564-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["6564"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06564-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3312277\/v1","asserted-by":"object"}]},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,20]]},"assertion":[{"value":"31 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were approved by the regional ethics committee board (study Nr.: CEC SSM Oriente\/05012021) and carried out in accordance with the ethical standards of the institutional and\/or national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"FLG has a patent application for quinolone-based FAP-targeting agents for imaging and therapy in nuclear medicine and shares a consultancy group for iTheranostics. FLG is also an advisor at ABX, Telix, Alpha Fusion, and SOFIE Biosciences. The other authors declare no conflict of interest regarding this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}